News

The uniqueness of this vaccine is that it is produced in ciliates and covers nearly all variations of a certain parasite antigen – a worldwide novelty. This project

The capacity expansion at the plant will help in providing a reliable supply of high-quality products to meet the domestic demand for the company’s products including cardiovascular and

The prospective, randomized, double-blind, placebo-controlled Phase IIa trial is designed to enroll up about 24 patients with type 1 diabetes in-clinic for ten days. During the trial, patients

CSG is nephrology academic research organization with 300 affiliated clinics worldwide, while Medpace is contract research organization (CRO) with demonstrated expertise and experience in nephrology. NRX expects to

Currently, BUNAVAIL is under review at the US Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of 07 June 2014. If BUNAVAIL

Proceeds from the contract will be used to develop an inhaled PDGF receptor kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The VITA contract will fund

The claims of the patent cover methods of using biOasis’ brain penetrating drug delivery vector, Transcend, coupled with a lysosomal storage disease enzyme for the treatment of lysosomal

In addition, beginning 24 months after execution of the agreement, CryoLife has the right to acquire the ProCol product line from Hancock Jaffe. Key aspects of transaction: –

iBio intellectual property vice president Dr Wayne P. Fitzmaurice noted that the antibodies covered by these patents are designed to block critical functions of the influenza virus necessary